Maraviroc

Paul G. Auwaerter, M.D., Paul A. Pham, Pharm.D. BCPS

INDICATIONS

Only recommended for patients with CCR5-tropic HIV-1 infection.

Used with other ARVs in ART-experienced adult patients infected with CCR5 (R5)-tropic HIV-1.
Used in combination with other ARVs in ART-naive adult patients infected with CCR5 (R5)-tropic HIV-1 (not a DHHS preferred first-line agent)
FDA-approved for adults and pediatric patients 2 years and older weighing at least 2 kg.

There's more to see -- the rest of this topic is available only to subscribers.